A systematic review of meta-analyses assessing the validity of tumour response endpoints as surrogates for progression-free or overall survival in cancer
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
A systematic review of meta-analyses assessing the validity of tumour response endpoints as surrogates for progression-free or overall survival in cancer
Authors
Keywords
-
Journal
BRITISH JOURNAL OF CANCER
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2020-09-11
DOI
10.1038/s41416-020-01050-w
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Combining tumour response and progression free survival as surrogate endpoints for overall survival in advanced colorectal cancer
- (2020) E.G. Elia et al. Cancer Epidemiology
- Surrogacy of intermediate endpoints for overall survival in randomized controlled trials of first-line treatment for advanced soft tissue sarcoma in the pre- and post-pazopanib era: a meta-analytic evaluation
- (2019) Kazuhiro Tanaka et al. BMC CANCER
- Complete response associated with immune checkpoint inhibitors in advanced non-small-cell lung cancer: a meta-analysis of nine randomized controlled trials
- (2019) Jie Li et al. Cancer Management and Research
- Evaluation of Overall Response Rate and Progression-Free Survival as Potential Surrogate Endpoints for Overall Survival in Immunotherapy Trials
- (2018) Sirisha L. Mushti et al. CLINICAL CANCER RESEARCH
- Meta-analyses evaluating surrogate endpoints for overall survival in cancer randomized trials: A critical review
- (2018) Marion Savina et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Use of depth of response to predict progression-free survival in relapsed or refractory multiple myeloma: Evaluation of results from 102 clinical trials
- (2018) Naveen Mangal et al. HEMATOLOGICAL ONCOLOGY
- Surrogate end points for overall survival in trials of PD-(L)1 inhibitors for urinary cancers: a systematic review
- (2018) Omar Abdel-Rahman Immunotherapy
- Do Surrogate Endpoints Better Correlate with Overall Survival in Studies That Did Not Allow for Crossover or Reported Balanced Postprogression Treatments? An Application in Advanced Non–Small Cell Lung Cancer
- (2018) Mahmoud Hashim et al. VALUE IN HEALTH
- Defining the Most Appropriate Primary End Point in Phase 2 Trials of Immune Checkpoint Inhibitors for Advanced Solid Cancers
- (2018) Georgia Ritchie et al. JAMA Oncology
- Evaluation of classical clinical endpoints as surrogates for overall survival in patients treated with immune checkpoint blockers: a systematic review and meta-analysis
- (2018) Howard L. Kaufman et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Alternate Endpoints for Phase II Trials in Advanced Neuroendocrine Tumors
- (2018) Hiroshi Imaoka et al. ONCOLOGIST
- A systematic review of trial-level meta-analyses measuring the strength of association between surrogate end-points and overall survival in oncology
- (2018) Alyson Haslam et al. EUROPEAN JOURNAL OF CANCER
- Evaluation of objective response, disease control and progression-free survival as surrogate end-points for overall survival in anti–programmed death-1 and anti–programmed death ligand 1 trials
- (2018) Run-Cong Nie et al. EUROPEAN JOURNAL OF CANCER
- Does the use of targeted agents in advanced gastroesophageal cancer increase complete response? A meta-analysis of 18 randomized controlled trials
- (2018) Yanyang Peng et al. Cancer Management and Research
- The impact of high PD-L1 expression on the surrogate endpoints and clinical outcomes of anti-PD-1/PD-L1 antibodies in non-small cell lung cancer
- (2018) Kentaro Ito et al. LUNG CANCER
- Progression-free survival as a surrogate endpoint in advanced neuroendocrine neoplasms
- (2017) Hiroshi Imaoka et al. ENDOCRINE-RELATED CANCER
- Response rate as a potential surrogate for survival and efficacy in patients treated with novel immune checkpoint inhibitors: A meta-regression of randomised prospective studies
- (2017) Giandomenico Roviello et al. EUROPEAN JOURNAL OF CANCER
- Objective response rate is a possible surrogate endpoint for survival in patients with advanced, recurrent ovarian cancer
- (2017) Mohammed Kashif Siddiqui et al. GYNECOLOGIC ONCOLOGY
- Relationship between response rates and median progression-free survival in non-Hodgkin's lymphoma: A meta-analysis of published clinical trials
- (2017) Naveen Mangal et al. HEMATOLOGICAL ONCOLOGY
- Thirty-Month Complete Response as a Surrogate End Point in First-Line Follicular Lymphoma Therapy: An Individual Patient-Level Analysis of Multiple Randomized Trials
- (2017) Qian Shi et al. JOURNAL OF CLINICAL ONCOLOGY
- AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both
- (2017) Beverley J Shea et al. BMJ-British Medical Journal
- Surrogate Endpoints in Second-Line Trials of Targeted Agents in Metastatic Colorectal Cancer: A Literature-Based Systematic Review and Meta-Analysis
- (2017) Chiara Cremolini et al. Cancer Research and Treatment
- AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both
- (2017) Beverley J Shea et al. BMJ-British Medical Journal
- Response Rates as Predictors of Overall Survival: A Meta-Analysis of Acute Myeloid Leukemia Trials
- (2017) Suresh K. Agarwal et al. Journal of Cancer
- Milestone Analyses of Immune Checkpoint Inhibitors, Targeted Therapy, and Conventional Therapy in Metastatic Non–Small Cell Lung Cancer Trials
- (2017) Gideon M. Blumenthal et al. JAMA Oncology
- Correlations of survival with progression-free survival, response rate and disease control rate in advanced biliary tract cancer: a meta-analysis of randomised trials of first-line chemotherapy
- (2016) Toshikazu Moriwaki et al. BRITISH JOURNAL OF CANCER
- Correlation between overall survival and other endpoints in metastatic breast cancer with second- or third-line chemotherapy: Literature-based analysis of 24 randomized trials
- (2016) Liya Liu et al. BULLETIN DU CANCER
- Analysis of Response-Related and Time-to-event Endpoints in Randomized Trials of Gemcitabine-Based Treatment Versus Gemcitabine Alone as First-Line Treatment of Patients With Advanced Pancreatic Cancer
- (2016) Giuseppe Colloca et al. Clinical Colorectal Cancer
- Trial Level Analysis of Prostate-Specific Antigen-Related Versus Unrelated Endpoints in Phase III Trials of First-Line and Second-Line Medical Treatments of Patients With Metastatic Castration-Resistant Prostate Cancer
- (2016) Giuseppe Colloca et al. Clinical Genitourinary Cancer
- Analysis of Clinical End Points of Randomised Trials Including Bevacizumab and Chemotherapy versus Chemotherapy as First-line Treatment of Metastatic Colorectal Cancer
- (2016) G. Colloca et al. CLINICAL ONCOLOGY
- Progression-free survival as a surrogate for overall survival in first-line chemotherapy for advanced pancreatic cancer
- (2016) Tsuyoshi Hamada et al. EUROPEAN JOURNAL OF CANCER
- Evolution of Randomized Trials in Advanced/Metastatic Soft Tissue Sarcoma: End Point Selection, Surrogacy, and Quality of Reporting
- (2016) Alona Zer et al. JOURNAL OF CLINICAL ONCOLOGY
- Progression-Free Survival, Response Rate, and Disease Control Rate as Predictors of Overall Survival in Phase III Randomized Controlled Trials Evaluating the First-Line Chemotherapy for Advanced, Locally Advanced, and Recurrent Non–Small Cell Lung Carcinoma
- (2016) Kentaro Nakashima et al. Journal of Thoracic Oncology
- Relationship between Overall Survival and Response or Progression-Free Survival in Advanced Non–Small Cell Lung Cancer Patients Treated with Anti–PD-1/PD-L1 Antibodies
- (2016) Takehito Shukuya et al. Journal of Thoracic Oncology
- Statistical controversies in clinical research: an initial evaluation of a surrogate end point using a single randomized clinical trial and the Prentice criteria
- (2015) G. Heller ANNALS OF ONCOLOGY
- Statistical evaluation of surrogate endpoints with examples from cancer clinical trials
- (2015) Marc Buyse et al. BIOMETRICAL JOURNAL
- Meta-analyses of randomized controlled trials show suboptimal validity of surrogate outcomes for overall survival in advanced colorectal cancer
- (2015) Oriana Ciani et al. JOURNAL OF CLINICAL EPIDEMIOLOGY
- Overall Response Rate, Progression-Free Survival, and Overall Survival With Targeted and Standard Therapies in Advanced Non–Small-Cell Lung Cancer: US Food and Drug Administration Trial-Level and Patient-Level Analyses
- (2015) Gideon M. Blumenthal et al. JOURNAL OF CLINICAL ONCOLOGY
- Magnitude of the Benefit of Progression-Free Survival as a Potential Surrogate Marker in Phase 3 Trials Assessing Targeted Agents in Molecularly Selected Patients with Advanced Non-Small Cell Lung Cancer: Systematic Review
- (2015) Katsuyuki Hotta et al. PLoS One
- Surrogate endpoints in second-line treatment for mCRC: A systematic literature-based analysis from 23 randomised trials
- (2014) Clemens Giessen et al. ACTA ONCOLOGICA
- Clinical Trial Design in Small Cell Lung Cancer: Surrogate End Points and Statistical Evolution
- (2014) Myles Nickolich et al. Clinical Lung Cancer
- The use of surrogate outcomes in model-based cost-effectiveness analyses: a survey of UK Health Technology Assessment reports
- (2014) R Taylor et al. HEALTH TECHNOLOGY ASSESSMENT
- Evaluation of Progression-Free Survival as a Surrogate Endpoint for Survival in Chemotherapy and Targeted Agent Metastatic Colorectal Cancer Trials
- (2013) R. Sidhu et al. CLINICAL CANCER RESEARCH
- Surrogate End Points and Postprogression Survival in Renal Cell Carcinoma: An Analysis of First-Line Trials With Targeted Therapies
- (2013) Fausto Petrelli et al. Clinical Genitourinary Cancer
- Six-Month Progression-Free Survival as the Primary Endpoint to Evaluate the Activity of New Agents as Second-line Therapy for Advanced Urothelial Carcinoma
- (2013) Neeraj Agarwal et al. Clinical Genitourinary Cancer
- Correlation between overall survival and other endpoints in clinical trials of second-line chemotherapy for patients with advanced gastric cancer
- (2013) Kohei Shitara et al. Gastric Cancer
- Surrogate endpoints in metastatic breast cancer treated with targeted therapies: an analysis of the first-line phase III trials
- (2013) Fausto Petrelli et al. MEDICAL ONCOLOGY
- Progression-free survival as a surrogate endpoint for overall survival in glioblastoma: a literature-based meta-analysis from 91 trials
- (2013) K. Han et al. NEURO-ONCOLOGY
- Is blood pressure reduction a valid surrogate endpoint for stroke prevention? an analysis incorporating a systematic review of randomised controlled trials, a by-trial weighted errors-in-variables regression, the surrogate threshold effect (STE) and the biomarker-surrogacy (BioSurrogate) evaluation schema (BSES)
- (2012) Marissa N Lassere et al. BMC Medical Research Methodology
- Association between treatment effects on disease progression end points and overall survival in clinical studies of patients with metastatic renal cell carcinoma
- (2012) T E Delea et al. BRITISH JOURNAL OF CANCER
- Surrogate end points for survival in the target treatment of advanced non-small-cell lung cancer with gefitinib or erlotinib
- (2012) Xiaoqin Li et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Biomarkers and surrogate endpoints in clinical trials
- (2012) Thomas R. Fleming et al. STATISTICS IN MEDICINE
- Identification of potential surrogate end points in randomized clinical trials of aggressive and indolent non-Hodgkin's lymphoma: correlation of complete response, time-to-event and overall survival end points
- (2011) L. Lee et al. ANNALS OF ONCOLOGY
- Is response rate increment obtained by molecular targeted agents related to survival benefit in the phase III trials of advanced cancer?
- (2010) K. Tsujino et al. ANNALS OF ONCOLOGY
- Tumor response and progression-free survival as potential surrogate endpoints for overall survival in extensive stage small-cell lung cancer
- (2010) Nathan R. Foster et al. CANCER
- Stable Disease Is Not Preferentially Observed With Targeted Therapies and as Currently Defined Has Limited Value in Drug Development
- (2010) Tatiana Vidaurre et al. CANCER JOURNAL
- Progression-Free Survival Is Simply a Measure of a Drug’s Effect While Administered and Is Not a Surrogate for Overall Survival
- (2010) Julia Wilkerson et al. CANCER JOURNAL
- Assessment of tumor response as a surrogate endpoint of survival in recurrent/platinum-resistant ovarian carcinoma: A Gynecologic Oncology Group study
- (2010) Peter G. Rose et al. GYNECOLOGIC ONCOLOGY
- Response Rate Is Associated with Prolonged Survival in Patients with Advanced Non-small Cell Lung Cancer Treated with Gefitinib or Erlotinib
- (2010) Kazuyuki Tsujino et al. Journal of Thoracic Oncology
- Association between incremental gains in the objective response rate and survival improvement in phase III trials of first-line chemotherapy for extensive disease small-cell lung cancer
- (2009) K. Hotta et al. ANNALS OF ONCOLOGY
- Use of surrogate outcomes in cost-effectiveness models: A review of United Kingdom health technology assessment reports
- (2009) Julian Elston et al. INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE
- Evaluation of Tumor Response, Disease Control, Progression-Free Survival, and Time to Progression As Potential Surrogate End Points in Metastatic Breast Cancer
- (2008) Tomasz Burzykowski et al. JOURNAL OF CLINICAL ONCOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation